King v. Burwell Ruling Clears A Path For “Cures,” Avoids Disrupting ACA
This article was originally published in RPM Report
Executive Summary
The pharmaceutical industry didn’t have as much at stake in the second major Supreme Court ruling on the Affordable Care Act – but should still be celebrating the decision to upheld the Administration’s approach to exchanges.